Tadalafil
Product Images NDC 68071-2451

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 68071-2451). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 2451 3)

Tadalafil 5 mg tablets packaging label by NuCare Pharmaceuticals, Inc., NDC 68071-2451-3. The label indicates a 30-tablet quantity and includes storage instructions to keep at controlled temperature 68-77°F. It also shows manufacturer details, product number R1858030, and warnings to keep out of reach of children. The label features barcodes, lot, expiration, and serial number placeholders.*

FDA Label Image

Figure8 (Tadalafil Fig8)

A line graph showing change from baseline in IPSS (International Prostate Symptom Score) total score over 12 weeks of treatment comparing Tadalafil 5 mg and placebo. The graph depicts a greater reduction in symptoms with Tadalafil 5 mg than placebo, with data points at 0, 2, 4, 8, and 12 weeks. Statistical significance is indicated at 12 weeks.*

FDA Label Image

Figure1 (Tadalafil Figure1)

A set of four line graphs showing the effect of Tadalafil on blood pressure over time. The graphs illustrate differences in standing systolic and diastolic blood pressure, as well as supine systolic and diastolic blood pressure, measured over a 96-hour period comparing Tadalafil with placebo.*

FDA Label Image

Figure2 (Tadalafil Figure2)

Two line graphs showing the effect on systolic blood pressure in standing and supine positions over 24 hours post-dose. The top graph compares standing systolic blood pressure with Tadalafil 20 mg plus doxazosin 8 mg and doxazosin 8 mg alone. The bottom graph compares supine systolic blood pressure with the same treatments including a placebo plus doxazosin 8 mg.*

FDA Label Image

Figure3 (Tadalafil Figure3)

A line graph displaying systolic blood pressure (BP) in mmHg over 12 hours after administration of tadalafil or placebo. The graph compares four groups: 20 mg tadalafil at 08:00 with 8 mg doxazosin at 08:00, placebo at 08:00 with 8 mg doxazosin at 08:00, 20 mg tadalafil at 20:00 with 8 mg doxazosin at 08:00, and placebo at 20:00 with 8 mg doxazosin at 08:00. The y-axis shows systolic BP changes ranging approximately from -20 to +10 mmHg, and the x-axis shows time post administration from 0 to 12 hours.*

FDA Label Image

Figure4 (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for three dosing regimens: a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing following 5 consecutive days of administration. The graph shows concentration changes and variability for each dosing schedule up to 120 hours.*

FDA Label Image

Figure5 (Tadalafil Figure5)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment duration between Tadalafil 5 mg and placebo. The graph shows data points at 0, 4, 8, and 12 weeks, with Tadalafil demonstrating a greater decrease in score compared to placebo. A significance indicator (*) marks p<0.01 for the comparison.*

FDA Label Image

Figure6 (Tadalafil Figure6)

A line graph comparing change from baseline in IPSS total score over 12 weeks of treatment between Tadalafil 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline. The graph indicates statistically significant differences (p<0.01) in scores between Tadalafil and placebo over time.*

FDA Label Image

Figure7 (Tadalafil Figure7)

A line graph showing least-squares mean change from baseline over 26 weeks of therapy comparing Tadalafil/Finasteride combination to Placebo/Finasteride. The graph plots change with time points at 0, 4, 12, and 26 weeks, indicating greater reduction in mean change for Tadalafil/Finasteride treatment.*

FDA Label Image

Structure (Tadalafil Structure)

Chemical structure of Tadalafil depicted as a molecular diagram showing its core fused ring system and functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.